Tetrodotoxin-sensitive neuronal voltage-gated sodium channel (TTX-s VGSC)

Tetrodotoxin-sensitive neuronal voltage-gated sodium channels (TTX-s VGSCs) are a group of transmembrane proteins essential for the generation and conduction of electrical signals in the nervous system. This group includes the isoforms Nav1.1, Nav1.2, Nav1.3, Nav1.6, and Nav1.7, which are distinguished by their high sensitivity to the neurotoxin tetrodotoxin (TTX) at nanomolar concentrations [1][2]. These channels open in response to membrane depolarization, allowing an influx of sodium ions that triggers the rising phase of the action potential [2]. They are critical therapeutic targets for a variety of conditions; for example, Nav1.1 and Nav1.2 are primary targets for anti-epileptic drugs, while Nav1.7 is a major focus for novel analgesics due to its role in peripheral pain signaling [3][5]. Mutations in the genes encoding these channels (e.g., SCN1A, SCN9A) are associated with severe disorders such as Dravet syndrome and inherited erythromelalgia [4]. Pharmacological modulation of these channels involves pore-blocking agents or gating modifiers, though achieving selectivity between isoforms remains a significant challenge to minimize side effects like dizziness or cardiac toxicity [6][7].

Other names

TTX-sensitive sodium channelTTX-s Na+ channelNeuronal TTX-sensitive sodium channelVoltage-gated sodium channel type 1Voltage-gated sodium channel type 2Voltage-gated sodium channel type 3Voltage-gated sodium channel type 6Voltage-gated sodium channel type 7

Drugs targeting these channels typically act as pore blockers that physically obstruct the ion conduction pathway or as gating modifiers that bind to the voltage-sensing domains to stabilize the non-conducting inactivated state, thereby reducing neuronal firing [1][6][7].